Immune checkpoints are receptors that modulate immunological self-tolerance. This new class of therapeutics has already revolutionized immuno-oncology. However, it is now known that immune checkpoint therapy also shows promising results in cardiovascular diseases. This is consistent with the “inflammatory hypothesis of atherosclerosis”. This project investigates the translational potential of immune checkpoint modulation in cardiovascular diseases.

Further information here.